Filtern
Volltext vorhanden
- ja (7)
Gehört zur Bibliographie
- ja (7)
Dokumenttyp
Sprache
- Englisch (7)
Schlagworte
- GFAP (2)
- biomarker (2)
- disease progression (2)
- frontotemporal dementia (2)
- ALS (1)
- Alzheimer’s dementia (1)
- Brain atrophy (1)
- CSF (1)
- CSVD (1)
- Chronic heart failure (1)
- Cognitive decline (1)
- Glial fibrillary acidic protein (1)
- MRI criteria (1)
- MS (1)
- Memory dysfunction (1)
- OCB (1)
- PPAR-gamme (1)
- SOD1 mutations (1)
- age (1)
- aphasia (1)
- assessment of cognitive disorders/dementia (1)
- atlas‐based volumetry (1)
- central nervous system (1)
- chitinase-3-like protein 1 (1)
- cognitive impairment (1)
- cognitive neuropsychology in dementia (1)
- conversion (1)
- delays progression (1)
- heart failure (1)
- hexanucleotide repeat (1)
- longitudinal magnetic resonance imaging (1)
- monocycline (1)
- multiple sklerosis (1)
- neurofilament light chain (1)
- neurofilaments (1)
- nonalcoholic steatohepatitis (1)
- phosphorylated tau protein (1)
- primary progressive aphasia (1)
- renal function (1)
- sample size calculation (1)
- transgenic mouse model (1)
- volumetric MRI (1)
- white matter hyperintensities (1)
Institut
- Neurologische Klinik und Poliklinik (5)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (4)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (2)
- Medizinische Klinik und Poliklinik I (2)
- Comprehensive Cancer Center Mainfranken (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
Background
With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the literature, but cognitive scores are still lacking. This study followed disease progression predominantly in language-based performance within 1 year and defined a PPA sum score which can be used in therapeutic interventions.
Methods
We assessed 28 patients with nonfluent variant PPA, 17 with semantic variant PPA, 13 with logopenic variant PPA, and 28 healthy controls in detail for 1 year. The most informative neuropsychological assessments were combined to a sum score, and associations between brain atrophy were investigated followed by a sample size calculation for clinical trials.
Results
Significant absolute changes up to 20% in cognitive tests were found after 1 year. Semantic and phonemic word fluency, Boston Naming Test, Digit Span, Token Test, AAT Written language, and Cookie Test were identified as the best markers for disease progression. These tasks provide the basis of a new PPA sum score. Assuming a therapeutic effect of 50% reduction in cognitive decline for sample size calculations, a number of 56 cases is needed to find a significant treatment effect. Correlations between cognitive decline and atrophy showed a correlation up to r = 0.7 between the sum score and frontal structures, namely the superior and inferior frontal gyrus, as well as with left-sided subcortical structures.
Conclusion
Our findings support the high performance of the proposed sum score in the follow-up of PPA and recommend it as an outcome measure in intervention studies.